A 300 IR sublingual tablet is an effective, safe treatment for house dust mite–induced allergic rhinitis: An international, double-blind, placebo-controlled, randomized phase III clinical trial

Pascal Demoly, Jonathan Corren, Peter Creticos, Frédéric De Blay, Philippe Gevaert, Peter Hellings, Krzysztof Kowal, Martine Le Gall, Natalia Nenasheva, Giovanni Passalacqua, Oliver Pfaar, Miguel Tortajada-Girbés, Carmen Vidal, Margitta Worm, Thomas B. Casale

Open source

DOI: 10.1016/j.jaci.2020.07.036
Published: 2021-03
Container: Journal of Allergy and Clinical Immunology
Publisher: Elsevier BV
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.jaci.2020.07.036,
  title = {A 300 IR sublingual tablet is an effective, safe treatment for house dust mite–induced allergic rhinitis: An international, double-blind, placebo-controlled, randomized phase III clinical trial},
  author = {Pascal Demoly and Jonathan Corren and Peter Creticos and Frédéric De Blay and Philippe Gevaert and Peter Hellings and Krzysztof Kowal and Martine Le Gall and Natalia Nenasheva and Giovanni Passalacqua and Oliver Pfaar and Miguel Tortajada-Girbés and Carmen Vidal and Margitta Worm and Thomas B. Casale},
  year = {2021},
  journal = {Journal of Allergy and Clinical Immunology},
  doi = {10.1016/j.jaci.2020.07.036},
  url = {https://doi.org/10.1016/j.jaci.2020.07.036}
}

RIS

TY  - JOUR
TI  - A 300 IR sublingual tablet is an effective, safe treatment for house dust mite–induced allergic rhinitis: An international, double-blind, placebo-controlled, randomized phase III clinical trial
AU  - Pascal Demoly
AU  - Jonathan Corren
AU  - Peter Creticos
AU  - Frédéric De Blay
AU  - Philippe Gevaert
AU  - Peter Hellings
AU  - Krzysztof Kowal
AU  - Martine Le Gall
AU  - Natalia Nenasheva
AU  - Giovanni Passalacqua
AU  - Oliver Pfaar
AU  - Miguel Tortajada-Girbés
AU  - Carmen Vidal
AU  - Margitta Worm
AU  - Thomas B. Casale
PY  - 2021
JO  - Journal of Allergy and Clinical Immunology
DO  - 10.1016/j.jaci.2020.07.036
UR  - https://doi.org/10.1016/j.jaci.2020.07.036
ER  -

APA

Demoly, P., Corren, J., Creticos, P., Blay, F. D., Gevaert, P., Hellings, P., Kowal, K., Gall, M. L., Nenasheva, N., Passalacqua, G., Pfaar, O., Tortajada-Girbés, M., Vidal, C., Worm, M., & Casale, T. B. (2021). A 300 IR sublingual tablet is an effective, safe treatment for house dust mite–induced allergic rhinitis: An international, double-blind, placebo-controlled, randomized phase III clinical trial. Journal of Allergy and Clinical Immunology. https://doi.org/10.1016/j.jaci.2020.07.036

Source records

crossref · retrieved 2026-09-26T22:54:54.569Z